The Ultimate Obesity Drug Battle: Mounjaro vs. Wegovy & Bimagrumab (feat. Weight Loss Medications, Drug Repositioning, Eli Lilly, Novo Nordisk Stock Price)

What if I told you the battle for the best obesity drug isn’t about who’s the biggest name—it’s about who’s got the secret weapon hidden in plain sight?

Wegovy, Mounjaro, and Bimagrumab are fighting for the crown—but guess what? One of them is quietly stealing the show. Want to know which one? Get ready to dive into a weight-loss war that’ll leave you questioning everything you thought you knew about these meds. This is no ordinary showdown. The twist? It’s coming from somewhere you least expect…

(Up to line 35 is the previous content, and from line 36 onwards, it contains the latest updates.)

The Power of Repositioning: A Pharma Secret

1. Sometimes, drugs already on the market or in clinical trials end up being more effective for diseases other than the one they were originally created for.
2. This accidental discovery of new uses for old drugs is called Drug Repositioning—it’s like finding a hidden gem you didn’t know you had.
3. Drug repositioning is a favorite of pharmaceutical companies because the clinical trials for side effects have already been done during the drug’s original development. Less work, more profit!
4. Since the drug has already gone through earlier trial phases, you can skip straight to Phase 2 or 3, making the whole process faster and easier.
5. Shortening clinical trials means cutting down on both time and cost. So, it’s a win-win for the companies—and ultimately for us.
6. Drug repositioning also has a significantly higher chance of approval compared to new drugs.
7. Even if a new drug passes Phase 2 trials, it only has a 10% chance of making it through to approval after Phase 3. Not great odds!
8. On the other hand, repositioned drugs have about a 25% chance of approval—way better odds. For pharma companies, that’s a potential jackpot.

The Rise of Obesity Medications: A Diabetes Side Hustle

9. While developing diabetes drugs, researchers ended up with a medication that was great for treating obesity, too.
10. Drugs like Saxenda and Wegovy came from this kind of repurposing. Talk about a side hustle!
11. That Wegovy is the same drug that Elon Musk reportedly used to shed some pounds.
12. Wegovy is mainly injected into the belly. It’s not glamorous, but hey, it works!
13. Wegovy helps you lose an average of 15% of your body weight per year, which beats Saxenda’s 9% weight loss.
14. While Saxenda needs a daily injection, Wegovy only requires one shot a week. That’s a huge plus, right?
15. Globally, Wegovy has already surpassed Saxenda in terms of sales and popularity. Wegovy’s taking the lead!
16. Since both Saxenda and Wegovy are made by Novo Nordisk, it doesn’t matter much to the company that Wegovy is outpacing Saxenda.

Mounjaro: A New Contender in the Ring

19. But hold up—Mounjaro, from Eli Lilly, might be the real challenger to Novo Nordisk’s dominance.
20. Mounjaro has already been approved by the FDA for diabetes treatment. Now, it’s waiting for approval for obesity treatment.
21. Mounjaro is also in clinical trials in other countries, expanding its potential use beyond just diabetes.
22. Mounjaro offers the same once-a-week injection as Wegovy, but it’s more powerful than Wegovy. That’s a game-changer.
23. While Wegovy helps with 15% weight loss per year, Mounjaro has shown 21% weight loss at 10 mg and 23% at 15 mg. Now that’s impressive!
24. Both Saxenda and Wegovy work by increasing insulin production in the pancreas and sending a signal to your brain to stop eating. Simple but effective.
25. Mounjaro doesn’t just do what Wegovy and Saxenda do—it also targets a hormone called GIP, which makes it even more effective at helping you shed the pounds.

The High Cost of Weight Loss: Pricing the Meds

28. Mounjaro and Wegovy aren’t that far apart in price.
29. In the U.S., Wegovy costs about $341 per dose, while Mounjaro comes in at $259 per dose. It’s a bit cheaper, but both are pricey.
30. With weekly doses, the monthly cost of Wegovy is $1,536, and Mounjaro’s monthly cost is $1,168. It’s a serious investment either way.

The Obesity Treatment Market Explosion

31. The World Health Organization (WHO) expects the global obesity treatment market to grow by over 30% per year. The future is looking fat—and in the good way!
32. The main downside of current treatments is that they all require injections. No fun, right?
33. Turns out, many people aren’t fans of injections. They’d rather pass on the shot.
34. Eli Lilly is working on turning Mounjaro from an injectable to a pill format in clinical trials.
35. If Mounjaro is released as an oral obesity medication, it could be a game-changer in the diet industry.

(Up to line 35 is the previous content, and from line 36 onwards, it contains the latest updates.)

Repositioning the Future: Mounjaro vs. Novo Nordisk

36. From a pharmaceutical company perspective, Eli Lilly’s Mounjaro could push Novo Nordisk’s Wegovy and Saxenda out of the market.
37. In fact, Novo Nordisk’s stock price has been on a continuous decline since the second half of 2024.
38. Mounjaro has already started to overshadow Wegovy and Saxenda, creating some serious competition in the obesity treatment market.

The Next Frontier: Saving Muscle While Losing Fat

39. The next big thing in obesity treatment will likely focus on preserving muscle mass while reducing fat.
40. The problem with current obesity treatments is that they don’t just burn fat; they can also cause muscle loss.
41. Without exercise, up to 40% of the weight lost with obesity treatments could come from muscle mass.
42. Pharmaceutical companies are now focusing on research to ensure that only fat is lost while preserving muscle mass.

The Rise of Bimagrumab: A Muscle-Saving Hero

43. Bimagrumab is becoming more prominent in this space.
44. Clinical trials are underway combining Bimagrumab with Wegovy or Mounjaro for the treatment of diabetes and obesity.
45. Combining Wegovy with Bimagrumab led to a 22.1% weight loss over 72 weeks.
46. Of the weight lost, 92.8% was fat, with almost no muscle loss.
47. When Bimagrumab is used alone, it results in a 10.8% weight loss, but the muscle mass actually increases by 2.3%.
48. Bimagrumab was originally developed for muscle-wasting treatment.
49. Versanis Bio held the rights to Bimagrumab and worked with Novo Nordisk to conduct the combined trials with Wegovy.
50. In July 2023, Eli Lilly acquired Versanis Bio, adding Bimagrumab to its Mounjaro trials.
51. Bimagrumab is another example of a drug repositioning product.
52. Initially developed for muscle-wasting, Bimagrumab didn’t show significant results as a standalone treatment.
53. However, its repositioning as an obesity treatment seems to be uncovering new potential value.

The Next Obesity Drug War: Fat Loss Meets Muscle Gain — A New Era or Another Failed Dream?

Forget everything you thought you knew about weight loss meds—because the next big thing might just be a two-for-one deal: fat loss AND muscle gain. Sounds like a dream, right? But it’s not too far off. The next obesity drug could finally make those dreams a reality. And hey, even failed drugs might make a comeback—thanks to drug repositioning. It’s like that old saying: ‘Never count out a fighter until the final bell.’ So, keep an eye on the clinical trials, because what’s dead today might just rise from the ashes tomorrow.